October 22–26, 2025, AACR-NCI-EORTC International Conference

1)Discovery and development of a highly cooperative and potent pan-KRAS degrader. 2)Identification of first-in-class paralog selective SMARCA4 degraders for treatment of hematological and prostate malignancies. 3)Discovery of highly selective, potent

April 25-30, 2025, American Association for Cancer Research

1)Identification of an orally bio-available SMARCA2 selective degrader for treatment of SMARCA4 mutant cancers. 2)Discovery and development of a highly differentiated, efficacious, first-in-class anti-SIRPα/β dual antibody with single agent phagocytosis

September 30- October 3, 2024, Discovery on Target

1) Discovery and Development of pan-KRAS Degraders for Cancer Therapyn 2) Efficacy of a First-in-Class Polymerase Theta Degrader in Preclinical Cancer Models

September 1-5, 2024, XXVIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2024)

1) Distinctive Roles for Small Molecule Inhibitors of Immune Checkpoint Proteins (LE072)

April 5- 10, 2024, AACR Conference

1) SMARCA 2/4 Degraders Relieve The Differentiation Block In AML via Changes In Chromatin Looping and Accessibility2) Paralogue Selectivity p300 Degraders Induce Synthetic Lethality in Pre-Clinical Models of CBP- Deficient

April 1- 4, 2024, Drug Discovery Chemistry

1) A Highly Differentiated Small Molecule Immune Checkpoint Inhibitor Dually Targeting PD-L1 And A2AR for Cancer Therapy2) Targeting CBM, A Tri Protein Signalling Hub, by Inhibition Of MALT1 for the